5-Year Follow-Up Study Confirms Safety and Efficacy of Trastuzumab Biosimilar in Patients with HER2-Positive Breast Cancer

TOP - October 2021 Vol 14, No 6 | Biosimilars - ESMO

During the 2021 European Society for Medical Oncology virtual meeting, 5-year follow-up data from a clinial trial showed comparable results related to cardiac safety and long-term efficacy between trastuzumab (Herceptin) and the biosimilar trastuzumab-dttb (SB3; Ontruzant) in patients with HER2-positive, early or locally advanced breast cancer. These findings were reported in a poster presentation by Xavier Pivot, MD, PhD, General Director, Centre Paul Strauss, Institut de Cancérologie Strasbourg Europe, France, and colleagues.

Study Details

In the main phase 3 trial, 875 patients with HER2-positive, early or locally advanced breast cancer received 8 cycles of SB3 or trastuzumab in combination with chemotherapy in the neoadjuvant setting. After completing the regimen and undergoing surgery, patients were given an additional 10 cycles of the biosimilar or the reference product to complete 12 months of therapy.

A total of 367 patients who completed the main phase 3 study went on to participate in the extension study. Of these, 181 received trastuzumab and 186 received SB3.

The primary end point was the incidence of congestive heart failure accompanied by a significant decline in left ventricular ejection fraction (LVEF). A significant change in LVEF was defined as an absolute decrease of ≥10% from baseline and a resulting LVEF <50%. Secondary end points included the incidence of cardiac death and other significant cardiac conditions, event-free survival (EFS), and overall survival (OS). During the follow-up period after adjuvant therapy, the incidence of asymptomatic significant LVEF decrease was rare (1 in the biosimilar group vs 2 in the trastuzumab group), with all patients recovering with LVEF ≥50%. There were no cases of symptomatic congestive heart failure or cardiac death reported in either group.

No difference was observed between SB3 and trastuzumab in terms of EFS and OS. There were 32 (17.2%) events and 38 (21.0%) events reported among patients in the biosimilar and trastuzumab groups, respectively (hazard ratio, 0.78; P = .03). The 5-year EFS rates were 82.8% and 79.7% for SB3 and the reference product, respectively. Fourteen (7.5%) deaths and 23 (12.7%) deaths were reported in the biosimilar and trastuzumab groups, respectively (hazard ratio, 0.62; P = .017). The 5-year OS rates were 93.1% for SB3 and 86.7% for trastuzumab.

“This 5-year analysis of the subpopulation from the phase 3 study further supports similarity of SB3 and trastuzumab with comparable cardiac safety profile, and long-term efficacy,” noted Dr Pivot and colleagues in their poster.

FDA Approval

In January 2019, the FDA approved SB3 as a 150-mg single-dose vial for the treatment of patients with HER2-overexpressing breast cancer or metastatic gastric or gastroesophageal junction adenocarcinoma. This approval was based on data from 7 clinical trials, which demonstrated similarity in survival outcomes and safety between SB3 and trastuzumab in patients with HER2-positive adjuvant and metastatic breast cancer, as well as HER2-positive metastatic gastric cancer. In March 2020, the FDA approved SB3 as a 420-mg multidose vial.

Related Items
Updated NCCN Guidelines Lower Age for Initial Colorectal Cancer Screening
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in NCCN 2022 Highlights
Pembrolizumab Added to Best Supportive Care Extends Survival in Patients with Hepatocellular Carcinoma
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GI 2022 Highlights
Nivolumab plus Ipilimumab Yields High Rate of pCR in the Neoadjuvant Setting for Patients with Resectable MSI/dMMR Oeso-Gastric Adenocarcinoma
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GI 2022 Highlights
Trastuzumab Deruxtecan Shows Survival Benefit in HER2-Positive Advanced Gastric Cancers
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GI 2022 Highlights
Continuous Treatment with Enzalutamide and Docetaxel Reduces the Risk for Progression in Patients with Metastatic Castration-Resistant Prostate Cancer
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GU 2022 Highlights
Neoadjuvant Enfortumab Vedotin Therapy Promising in Patients with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GU 2022 Highlights
New Treatment Strategies for Patients with Advanced Melanoma
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in NCCN 2022 Highlights
The Future of Genetic Therapies and Value-Based Care in Oncology
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in AVBCC Summit Highlights
Community Provider Perspective: The Current and Future State of Cancer Care
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in AVBCC Summit Highlights
Biosimilars and the Road Ahead: Experts Discuss Opportunities and Challenges
William King
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in AVBCC Summit Highlights
Last modified: November 8, 2021